Molly Henderson Sells 6,583 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 6,583 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total transaction of $43,381.97. Following the completion of the sale, the chief financial officer now directly owns 93,546 shares of the company’s stock, valued at $616,468.14. This trade represents a 6.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Molly Henderson also recently made the following trade(s):

• On Thursday, December 19th, Molly Henderson sold 1,291 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total value of $10,328.00.

Phathom Pharmaceuticals Price Performance

Shares of Phathom Pharmaceuticals stock opened at $6.90 on Friday. Phathom Pharmaceuticals, Inc. has a 12-month low of $6.07 and a 12-month high of $19.71. The company’s fifty day simple moving average is $8.04 and its two-hundred day simple moving average is $12.50.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.57) by $0.25. The company had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same period in the previous year, the company earned ($0.76) earnings per share. On average, equities analysts expect that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers lifted its position in Phathom Pharmaceuticals by 17.1% during the second quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock valued at $568,000 after buying an additional 8,075 shares during the period. Marshall Wace LLP purchased a new position in Phathom Pharmaceuticals during the 2nd quarter valued at about $1,161,000. The Manufacturers Life Insurance Company grew its holdings in Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after purchasing an additional 1,339 shares during the period. SG Americas Securities LLC purchased a new stake in Phathom Pharmaceuticals in the third quarter worth about $244,000. Finally, Creative Planning increased its stake in shares of Phathom Pharmaceuticals by 25.7% during the third quarter. Creative Planning now owns 33,884 shares of the company’s stock valued at $613,000 after purchasing an additional 6,933 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PHAT shares. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.